APOLLO-1: randomized, placebo- and active-controlled phase 3 study investigating oliceridine (TRV130), a novel mu receptor G protein Pathway Selective (mu-GPS) modulator, for management of moderate to severe acute pain following bunionectomy

Skobieranda F.; Singla N.; Burt D.; Soergel D.

首页> 外文期刊>The journal of pain: official journal of the American Pain Society >APOLLO-1: randomized, placebo- and active-controlled phase 3 study investigating oliceridine (TRV130), a novel mu receptor G protein Pathway Selective (mu-GPS) modulator, for management of moderate to severe acute pain following bunionectomy

【24h】

APOLLO-1: randomized, placebo- and active-controlled phase 3 study investigating oliceridine (TRV130), a novel mu receptor G protein Pathway Selective (mu-GPS) modulator, for management of moderate to severe acute pain following bunionectomy

机译：Apollo-1：随机，安慰剂和主动控制的第3期研究调查奥丙酮（TRV130），一种新型MU受体G蛋白途径选择性（MU-GPS）调节剂，用于治疗中度至严重急性疼痛后抑结术后

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The journal of pain: official journal of the American Pain Society》 |2017年第1期|共2页
作者
Skobieranda F.; Singla N.; Burt D.; Soergel D.;
展开▼
作者单位

Lotus Clin Res Pasadena CA USA;

Lotus Clin Res Pasadena CA USA;

Lotus Clin Res Pasadena CA USA;

Lotus Clin Res Pasadena CA USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类诊断学;
关键词

相似文献

外文文献

1. APOLLO-1: randomized, placebo- and active-controlled phase 3 study investigating oliceridine (TRV130), a novel mu receptor G protein Pathway Selective (mu-GPS) modulator, for management of moderate to severe acute pain following bunionectomy [J] . Skobieranda F., Singla N., Burt D., The journal of pain: official journal of the American Pain Society . 2017,第4Suppla1期

机译：Apollo-1：随机，安慰剂和主动控制的第3期研究调查奥丙酮（TRV130），一种新型MU受体G蛋白途径选择性（MU-GPS）调节剂，用于治疗中度至严重急性疼痛后抑结术后
2. APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the μ-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy [J] . Eugene R Viscusi, Franck Skobieranda, David G Soergel, Journal of Pain Research . 2019,第2期

机译：APOLLO-1：一项随机安慰剂和一项主动控制的III期随机对照研究，旨在研究奥利替丁（μ阿片受体上的G蛋白偏向配体）奥利替丁（TRV130），以治疗中度至重度的拇囊炎切除术后急性疼痛
3. A randomized, Phase IIb study investigating oliceridine (TRV130), a novel μ-receptor G-protein pathway selective (μ-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty [J] . Neil Singla, Harold S Minkowitz, David G Soergel, Journal of Pain Research . 2017,第2期

机译：一项IIb期随机研究，研究了一种新的μ受体G蛋白途径选择性（μ-GPS）调节剂奥立啶（TRV130），用于治疗腹部成形术后的中度至重度急性疼痛
4. APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130) a G protein-biased ligand at the µ-opioid receptor for management of moderate-to-severe acute pain following bunionectomy [O] . Eugene R Viscusi, Franck Skobieranda, David G Soergel, 2019

机译：APOLLO-1：一项随机安慰剂和一项主动控制的III期随机对照研究研究了奥利替丁（TRV130）一种在阿片类药物受体上受G蛋白偏斜的配体用于治疗中度至重度的拇囊炎切除术后急性疼痛
5. (223) APOLLO-1: randomized, placebo- and active-controlled phase 3 study investigating oliceridine (TRV130), a novel μ receptor G protein Pathway Selective (μ-GPS) modulator, for management of moderate to severe acute pain following bunionectomy [O] . F. Skobieranda, N. Singla, D. Burt, 2017

机译：（223）Apollo-1：随机，安慰剂和主动控制的第3期研究调查奥霉素（TRV130），一种新型μ受体G蛋白途径选择性（μ-GPS）调节剂，用于治疗抑结术后的中度至重度急性疼痛

APOLLO-1: randomized, placebo- and active-controlled phase 3 study investigating oliceridine (TRV130), a novel mu receptor G protein Pathway Selective (mu-GPS) modulator, for management of moderate to severe acute pain following bunionectomy

著录项

相似文献

相关主题

期刊订阅